Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Biogen (BIIB) to $139 from $156 and keeps a Market Perform rating on the ...

CyberArk Software Ltd. announced Thursday that it acquired Zilla Security, a cybersecurity startup specializing in identity ...

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Good morning, Boston. Spring training has begun, and here are the five things you need to know, including Biogen cutbacks, CVS's new CEO, Eastern Nazarene sale, spring training, Rat Day, and more Vale ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) traded down 6.8% during trading on Wednesday after Bank Of America (Bofa) lowered ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...